BIOMAT Database Logo BIOMAT Database Logo

The treatment of diffuse undifferentiated non-Hodgkin's lymphoma in children: the Childrens Cancer Study Group experience. 1985

R D Jenkin, and J R Anderson, and R R Chilcote, and P Coccia, and P Exelby, and J Kersey, and C R Kjeldsberg, and J Kushner, and A T Meadows, and S Siegel

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R D Jenkin, and J R Anderson, and R R Chilcote, and P Coccia, and P Exelby, and J Kersey, and C R Kjeldsberg, and J Kushner, and A T Meadows, and S Siegel
The role of surgery in abdominal non-Hodgkin's lymphoma: experience from the Childrens Cancer Study Group.
February 1992, Journal of pediatric surgery,
R D Jenkin, and J R Anderson, and R R Chilcote, and P Coccia, and P Exelby, and J Kersey, and C R Kjeldsberg, and J Kushner, and A T Meadows, and S Siegel
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.
June 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R D Jenkin, and J R Anderson, and R R Chilcote, and P Coccia, and P Exelby, and J Kersey, and C R Kjeldsberg, and J Kushner, and A T Meadows, and S Siegel
CNOP for diffuse aggressive non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience.
April 2002, Leukemia & lymphoma,
R D Jenkin, and J R Anderson, and R R Chilcote, and P Coccia, and P Exelby, and J Kersey, and C R Kjeldsberg, and J Kushner, and A T Meadows, and S Siegel
Non-Hodgkin's lymphoma in children; diffuse lymphoblastic histology; diffuse non-lymphoblastic histology; LSA2-L2 experience.
October 1988, Anales espanoles de pediatria,
R D Jenkin, and J R Anderson, and R R Chilcote, and P Coccia, and P Exelby, and J Kersey, and C R Kjeldsberg, and J Kushner, and A T Meadows, and S Siegel
Adjuvant low dose radiation in childhood non-Hodgkin's lymphoma (report from the United Kingdom Childrens' Cancer Study Group--UKCCSG).
October 1984, British journal of cancer,
R D Jenkin, and J R Anderson, and R R Chilcote, and P Coccia, and P Exelby, and J Kersey, and C R Kjeldsberg, and J Kushner, and A T Meadows, and S Siegel
Prognosis and treatment after relapse of acute lymphoblastic leukemia and non-Hodgkin's lymphoma: 1985. A report from the Childrens Cancer Study Group.
July 1986, Cancer,
R D Jenkin, and J R Anderson, and R R Chilcote, and P Coccia, and P Exelby, and J Kersey, and C R Kjeldsberg, and J Kushner, and A T Meadows, and S Siegel
Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
April 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R D Jenkin, and J R Anderson, and R R Chilcote, and P Coccia, and P Exelby, and J Kersey, and C R Kjeldsberg, and J Kushner, and A T Meadows, and S Siegel
Localised non-Hodgkin's lymphoma: the Sheffield Lymphoma Group experience (1970-1995).
December 1998, International journal of oncology,
R D Jenkin, and J R Anderson, and R R Chilcote, and P Coccia, and P Exelby, and J Kersey, and C R Kjeldsberg, and J Kushner, and A T Meadows, and S Siegel
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
July 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R D Jenkin, and J R Anderson, and R R Chilcote, and P Coccia, and P Exelby, and J Kersey, and C R Kjeldsberg, and J Kushner, and A T Meadows, and S Siegel
Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience.
July 1999, Leukemia & lymphoma,
Copied contents to your clipboard!